Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127497251 | 12749725 | 1 | I | 2014 | 20160908 | 20160915 | 20160915 | EXP | BR-ASTRAZENECA-2016SE97205 | ASTRAZENECA | 61.00 | YR | F | Y | 0.00000 | 20160915 | CN | BR | BR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127497251 | 12749725 | 1 | SS | ATENOLOL. | ATENOLOL | 1 | Unknown | 50 MG | 0 | ||||||||||
127497251 | 12749725 | 2 | PS | ATACAND HCT | CANDESARTAN CILEXETILHYDROCHLOROTHIAZIDE | 1 | Oral | 16/12.5 MG EVERY DAY | U | U | 21093 | TABLET | |||||||
127497251 | 12749725 | 3 | SS | CALCIUM | CALCIUM | 1 | Unknown | 0 | |||||||||||
127497251 | 12749725 | 4 | C | NORVASC | AMLODIPINE BESYLATE | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127497251 | 12749725 | 2 | Hypertension |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127497251 | 12749725 | OT |
127497251 | 12749725 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127497251 | 12749725 | Blood pressure increased | |
127497251 | 12749725 | Calcium intoxication | |
127497251 | 12749725 | Chest pain | |
127497251 | 12749725 | Fatigue | |
127497251 | 12749725 | Intentional product misuse | |
127497251 | 12749725 | Thyroid cancer |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |